Clinical trial

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

NCT00255463

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-01-01

PhasePHASE2

Study timeline

Study start (unknown)2004-01-01Date precision: month

Registry last updated2009-04-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

AnastrazoleDRUG

GefitinibDRUG · verified · RxNorm: gefitinib

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

LondonUnited Kingdom1 BudapestHungary1 PragueCzechia1 MontpellierFrance1 ManchesterUnited Kingdom1 StockholmSweden1 Clermont-FerrandFrance1 LisbonPortugal1 VillejuifFrance1 GothenburgSweden1 BrnoCzechia1 DebrecenHungary1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00255463 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.